Heidelberg Pharma announces progress into Cohort 6 with its proprietary ATAC candidate HDP-101 in Phase I/IIa multiple myeloma study
- Data from HDP-101 dose escalation shows first objective responses and partial remissions in Cohort 5
- Amended protocol includes expanded Cohort 6 with dose optimization, including three parallel arms at different dosing regimens
- Revolutionizing treatment options for multiple myeloma patients with its proprietary novel payload with a unique mode of action
Ladenburg, Germany, 18 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announces that it will be advancing into an expanded Cohort 6 dose escalation following submission of a protocol amendment to the US Food and Drug Administration (FDA) for its Phase I/IIa study with lead ATAC candidate HDP-101 for the treatment of multiple myeloma.
